Clarisse Lobo

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

Giuseppe Saglio, Dong‐Wook Kim, Surapol Issaragrisil et al. · New England Journal of Medicine · 2010 · 1.7K citations · Full text

Relationship between oxidative stress, glutathione S-transferase polymorphisms and hydroxyurea treatment in sickle cell anemia

Danilo Grünig Humberto da Silva, Edis Belini, Lidiane S. Torres et al. · Blood Cells Molecules and Diseases · 2011 · 57 citations

Hydroxyurea Treatment, Redox Signaling, Heme Degradation +7

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

Timothy P. Hughes, Andreas Hochhaus, Hagop M. Kantarjian et al. · Haematologica · 2014 · 48 citations · Full text

ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Timothy P. Hughes, Andreas Hochhaus, Giuseppe Saglio et al. · Blood · 2010 · 43 citations

Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial

Giuseppe Saglio, Dong-Wook Kim, Surapol Issaragrisil et al. · Blood · 2009 · 36 citations